El Bairi Khalid, Trapani Dario, Petrillo Angelica, Le Page Cécile, Zbakh Hanaa, Daniele Bruno, Belbaraka Rhizlane, Curigliano Giuseppe, Afqir Said
Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco.
European Institute of Oncology, IRCCS, Milan, Italy.
Eur J Cancer. 2020 Dec;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22.
Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.
自去年12月爆发以来，由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）已以大流行的规模在全球迅速传播，因此被视为全球突发公共卫生事件。除了强化支持治疗外，目前针对COVID-19的治疗选择有限，迄今为止报道的疗效尚不明确或效果一般。药物重新利用是一种积极的机制，即在已批准药物的原始适应症范围之外使用这些药物，并加速新治疗选择的发现。随着COVID-19的出现，药物重新利用已大量应用于早期临床试验。在本综述中，我们讨论了一些用于治疗COVID-19的重新利用的抗癌药物，这些药物正在临床试验中进行研究或拟用于临床试验。
